Drug Discovery 아웃소싱 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of Drug Discovery Outsourcing Market

The global drug discovery outsourcing market was valued at USD 8.08 billion in 2025 and is projected to grow from USD 8.75 billion in 2026 to USD 16.93 billion by 2034, registering a CAGR of 8.6% during the forecast period. North America dominated the global market with a 37.38% market share in 2025, supported by the strong presence of pharmaceutical companies, advanced contract research organizations (CROs), and increasing investment in drug development.

Drug discovery outsourcing enables pharmaceutical and biotechnology companies to delegate research activities such as target identification, hit identification, lead optimization, medicinal chemistry, biology services, and toxicology studies to specialized CROs. Outsourcing helps reduce development costs, accelerate research timelines, and provide access to advanced scientific expertise and digital technologies. The growing burden of chronic diseases, increasing complexity of drug development programs, and expanding biotech pipelines are major factors driving market growth. Furthermore, companies such as Charles River Laboratories, WuXi AppTec, Eurofins Scientific, and Evotec continue to strengthen their service capabilities through acquisitions, collaborations, and AI-enabled drug discovery platforms.

Market Trends

One of the most significant trends shaping the drug discovery outsourcing market is the growing adoption of artificial intelligence (AI), machine learning, and computational drug discovery platforms. CROs are increasingly utilizing AI for target identification, virtual screening, lead optimization, biomarker discovery, and candidate prioritization. These technologies improve research efficiency, reduce development timelines, and lower late-stage clinical failure risks. As pharmaceutical companies seek faster and more cost-effective drug discovery solutions, demand for AI-enabled outsourcing services continues to rise.

Market Drivers

The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, neurological diseases, and infectious diseases is significantly increasing demand for innovative therapies. As pharmaceutical and biotechnology companies expand their research pipelines, outsourcing drug discovery activities has become an effective strategy for reducing operational costs while gaining access to specialized scientific expertise. Increasing investments in personalized medicine, biologics, and precision therapeutics are also supporting market expansion.

Market Restraints

Despite strong growth potential, concerns regarding data security, intellectual property protection, and confidentiality continue to restrain market growth. Drug discovery projects involve highly valuable biological data, molecular structures, screening results, and proprietary research. Any security breach or unauthorized access can delay development programs and expose valuable intellectual property, making some companies cautious about outsourcing critical research activities.

Market Opportunities

The rapid expansion of contract research organizations (CROs) across emerging markets such as India, China, and Brazil presents substantial growth opportunities. Growing healthcare expenditure, favorable government initiatives, expanding laboratory infrastructure, and increasing pharmaceutical investments are encouraging multinational companies to outsource research activities to these cost-effective regions. Rising adoption of automation, cloud computing, and digital laboratory technologies further enhances outsourcing capabilities.

Market Challenges

A major challenge for the industry is the limited availability of highly specialized CROs in several developing countries. Many emerging markets still lack advanced infrastructure for medicinal chemistry, toxicology studies, computational biology, high-throughput screening, and translational research. This limits the outsourcing of highly complex drug discovery projects and slows market penetration in certain regions.

Segmentation Analysis

Based on service type, the chemistry services segment dominated the market in 2025 due to increasing demand for medicinal chemistry, compound synthesis, and lead optimization services. The biology services segment is expected to witness strong growth throughout the forecast period.

By discovery phase, the lead optimization segment accounted for the largest market share in 2025 as pharmaceutical companies increasingly outsource optimization activities to accelerate drug development. Hit identification is expected to register healthy growth over the forecast period.

Based on drug type, small molecules dominated the market with a 68.9% share in 2025, driven by continuous approvals of novel small-molecule therapies. The biologics segment is anticipated to experience faster growth as demand for biologic drugs continues to increase.

By therapeutic area, oncology remained the leading segment due to the growing global cancer burden and increasing investments in oncology drug development. Neurological disorders, cardiovascular diseases, and infectious diseases also continue to generate substantial outsourcing demand.

Based on end user, pharmaceutical and biotechnology companies accounted for the largest share in 2025 owing to rising R&D expenditure, expanding drug pipelines, and increasing dependence on CROs for specialized research services.

Regional Outlook

North America remained the largest regional market with a value of USD 3.02 billion in 2025. The region benefits from advanced research infrastructure, high pharmaceutical R&D spending, widespread adoption of outsourcing services, and the presence of leading CROs. The U.S. market alone is estimated to reach USD 2.87 billion in 2026, maintaining its dominant global position.

Europe is expected to reach USD 2.33 billion in 2026, supported by increasing outsourcing activities, favorable regulatory frameworks, and expanding pharmaceutical research across Germany, the U.K., and other European countries.

Asia Pacific is projected to reach USD 2.45 billion in 2026, driven by the rapid expansion of biotechnology companies, increasing CRO infrastructure, government support for life sciences research, and growing pharmaceutical manufacturing capabilities in China, India, and Japan.

Latin America and the Middle East & Africa are anticipated to witness steady growth as investments in healthcare infrastructure, research institutes, and pharmaceutical collaborations continue to increase.

Competitive Landscape

The global drug discovery outsourcing market is highly competitive, with major players focusing on acquisitions, strategic collaborations, AI integration, and expansion of laboratory capabilities to strengthen their market positions. Leading companies include Charles River Laboratories, WuXi AppTec, Labcorp, Evotec, Eurofins Scientific, Reaction Biology, Pharmaron, Aragen Life Sciences, Sai Life Sciences, and Crown Bioscience. Recent strategic initiatives, including acquisitions, AI-driven discovery platforms, and expanded biologics capabilities, continue to improve service offerings and global competitiveness.

Key Industry Developments

Recent developments highlight the industry's rapid evolution. In July 2026, Eurofins Scientific acquired DiscoveryBioMed to strengthen human bioassay capabilities. In April 2026, WuXi AppTec showcased multiple oncology drug discovery innovations at AACR 2026. Sai Life Sciences partnered with Chemical.AI in March 2026 to integrate AI-powered retrosynthesis into discovery chemistry workflows. Charles River Laboratories acquired PathoQuest in January 2026 to expand biologics testing services. In October 2025, Pharmaron strengthened its protein science capabilities through the acquisition of Biortus Biosciences, while several collaborations across AI-based molecular modeling and drug discovery technologies continue to accelerate innovation.

Conclusion

The global drug discovery outsourcing market is positioned for robust growth as pharmaceutical and biotechnology companies increasingly rely on specialized CROs to improve research efficiency, reduce development costs, and accelerate drug discovery timelines. Rising chronic disease prevalence, expanding biotech pipelines, AI-enabled discovery platforms, and increasing investments in personalized medicine will continue driving market expansion. With the market expected to grow from USD 8.75 billion in 2026 to USD 16.93 billion by 2034, outsourcing is expected to remain a critical component of modern pharmaceutical research and innovation.

Segmentation By Service Type, Discovery Phase, Drug Type, Therapeutic Area, End User, and Region

By Service Type * Chemistry Services

• Synthetic Chemistry Services
• Analytical Chemistry Services
• Others
• Biology Services
  • In-vitro Profiling Services
  • Toxicology Services
  • Others

By Discovery Phase * Target Identification & Validation

• Hit Identification
• Hit-to-Lead
• Lead Optimization
• Others

By Drug Type * Small Molecules

• Biologics

By Therapeutic Area * Oncology

• Neurological Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Others

By End User * Pharmaceutical & Biotechnological Companies

• Academic & Research Institutes
• Others

By Region * North America (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country)

• U.S. (By Drug Type)
• Canada (By Drug Type)
• Europe (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
  • U.K. (By Drug Type)
  • Germany (By Drug Type)
  • France (By Drug Type)
  • Italy (By Drug Type)
  • Spain (By Drug Type)
  • Scandinavia (By Drug Type)
  • Rest of Europe (By Drug Type)
• Asia Pacific (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
  • China (By Drug Type)
  • Japan (By Drug Type)
  • India (By Drug Type)
  • Australia (By Drug Type)
  • Southeast Asia (By Drug Type)
  • Rest of Asia Pacific (By Drug Type)
• Latin America (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
  • Brazil (By Drug Type)
  • Mexico (By Drug Type)
  • Rest of Latin America (By Drug Type)
• Middle East & Africa (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
  • GCC (By Drug Type)
  • South Africa (By Drug Type)
  • Rest of Middle East & Africa (By Drug Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Executive Summary

2. Market Dynamics

• 2.1. Market Drivers
• 2.2. Market Restraints
• 2.3. Market Opportunities
• 2.4. Market Challenges
• 2.5. Market Trends

3. Key Insights

• 3.1. Prevalence of Key Disorders, Key Countries/Region, 2025
• 3.2. Overview of Healthcare Expenditure, Key Countries, 2025
• 3.3. Overview of R&D Expenditures, Key Players
• 3.4. Key Industry Developments - Mergers, Acquisitions & Partnerships

4. Global Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

• 4.1. Market Analysis, Insights and Forecast - By Service Type
  • 4.1.1. Chemistry Services
    • 4.1.1.1. Synthetic Chemistry Services
    • 4.1.1.2. Analytical Chemistry Services
    • 4.1.1.3. Others
  • 4.1.2. Biology Services
    • 4.1.2.1. In-vitro Profiling Services
    • 4.1.2.2. Toxicology Services
    • 4.1.2.3. Others
• 4.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 4.2.1. Target Identification & Validation
  • 4.2.2. Hit Identification
  • 4.2.3. Hit-to-Lead
  • 4.2.4. Lead Optimization
  • 4.2.5. Others
• 4.3. Market Analysis, Insights and Forecast - By Drug Type
  • 4.3.1. Small Molecules
  • 4.3.2. Biologics
• 4.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 4.4.1. Oncology
  • 4.4.2. Neurological Diseases
  • 4.4.3. Infectious Diseases
  • 4.4.4. Cardiovascular Diseases
  • 4.4.5. Others
• 4.5. Market Analysis, Insights and Forecast - By End User
  • 4.5.1. Pharmaceutical & Biotechnological Companies
  • 4.5.2. Academic & Research Institutes
  • 4.5.3. Others
• 4.6. Market Analysis, Insights and Forecast - By Region
  • 4.6.1. North America
  • 4.6.2. Europe
  • 4.6.3. Asia Pacific
  • 4.6.4. Latin America
  • 4.6.5. Middle East & Africa

5. North America Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Service Type
  • 5.1.1. Chemistry Services
    • 5.1.1.1. Synthetic Chemistry Services
    • 5.1.1.2. Analytical Chemistry Services
    • 5.1.1.3. Others
  • 5.1.2. Biology Services
    • 5.1.2.1. In-vitro Profiling Services
    • 5.1.2.2. Toxicology Services
    • 5.1.2.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 5.2.1. Target Identification & Validation
  • 5.2.2. Hit Identification
  • 5.2.3. Hit-to-Lead
  • 5.2.4. Lead Optimization
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Drug Type
  • 5.3.1. Small Molecules
  • 5.3.2. Biologics
• 5.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 5.4.1. Oncology
  • 5.4.2. Neurological Diseases
  • 5.4.3. Infectious Diseases
  • 5.4.4. Cardiovascular Diseases
  • 5.4.5. Others
• 5.5. Market Analysis, Insights and Forecast - By End User
  • 5.5.1. Pharmaceutical & Biotechnological Companies
  • 5.5.2. Academic & Research Institutes
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Country
  • 5.6.1. U.S.
    • 5.6.1.1. By Drug Type
  • 5.6.2. Canada
    • 5.6.2.1. By Drug Type

6. Europe Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Service Type
  • 6.1.1. Chemistry Services
    • 6.1.1.1. Synthetic Chemistry Services
    • 6.1.1.2. Analytical Chemistry Services
    • 6.1.1.3. Others
  • 6.1.2. Biology Services
    • 6.1.2.1. In-vitro Profiling Services
    • 6.1.2.2. Toxicology Services
    • 6.1.2.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 6.2.1. Target Identification & Validation
  • 6.2.2. Hit Identification
  • 6.2.3. Hit-to-Lead
  • 6.2.4. Lead Optimization
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Drug Type
  • 6.3.1. Small Molecules
  • 6.3.2. Biologics
• 6.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 6.4.1. Oncology
  • 6.4.2. Neurological Diseases
  • 6.4.3. Infectious Diseases
  • 6.4.4. Cardiovascular Diseases
  • 6.4.5. Others
• 6.5. Market Analysis, Insights and Forecast - By End User
  • 6.5.1. Pharmaceutical & Biotechnological Companies
  • 6.5.2. Academic & Research Institutes
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 6.6.1. U.K.
    • 6.6.1.1. By Drug Type
  • 6.6.2. Germany
    • 6.6.2.1. By Drug Type
  • 6.6.3. France
    • 6.6.3.1. By Drug Type
  • 6.6.4. Spain
    • 6.6.4.1. By Drug Type
  • 6.6.5. Italy
    • 6.6.5.1. By Drug Type
  • 6.6.6. Scandinavia
    • 6.6.6.1. By Drug Type
  • 6.6.7. Rest of Europe
    • 6.6.7.1. By Drug Type

7. Asia Pacific Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Service Type
  • 7.1.1. Chemistry Services
    • 7.1.1.1. Synthetic Chemistry Services
    • 7.1.1.2. Analytical Chemistry Services
    • 7.1.1.3. Others
  • 7.1.2. Biology Services
    • 7.1.2.1. In-vitro Profiling Services
    • 7.1.2.2. Toxicology Services
    • 7.1.2.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 7.2.1. Target Identification & Validation
  • 7.2.2. Hit Identification
  • 7.2.3. Hit-to-Lead
  • 7.2.4. Lead Optimization
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Drug Type
  • 7.3.1. Small Molecules
  • 7.3.2. Biologics
• 7.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 7.4.1. Oncology
  • 7.4.2. Neurological Diseases
  • 7.4.3. Infectious Diseases
  • 7.4.4. Cardiovascular Diseases
  • 7.4.5. Others
• 7.5. Market Analysis, Insights and Forecast - By End User
  • 7.5.1. Pharmaceutical & Biotechnological Companies
  • 7.5.2. Academic & Research Institutes
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. Japan
    • 7.6.1.1. By Drug Type
  • 7.6.2. Australia
    • 7.6.2.1. By Drug Type
  • 7.6.3. China
    • 7.6.3.1. By Drug Type
  • 7.6.4. India
    • 7.6.4.1. By Drug Type
  • 7.6.5. Southeast Asia
    • 7.6.5.1. By Drug Type
  • 7.6.6. Rest of Asia Pacific
    • 7.6.6.1. By Drug Type

8. Latin America Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Service Type
  • 8.1.1. Chemistry Services
    • 8.1.1.1. Synthetic Chemistry Services
    • 8.1.1.2. Analytical Chemistry Services
    • 8.1.1.3. Others
  • 8.1.2. Biology Services
    • 8.1.2.1. In-vitro Profiling Services
    • 8.1.2.2. Toxicology Services
    • 8.1.2.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 8.2.1. Target Identification & Validation
  • 8.2.2. Hit Identification
  • 8.2.3. Hit-to-Lead
  • 8.2.4. Lead Optimization
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Drug Type
  • 8.3.1. Small Molecules
  • 8.3.2. Biologics
• 8.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 8.4.1. Oncology
  • 8.4.2. Neurological Diseases
  • 8.4.3. Infectious Diseases
  • 8.4.4. Cardiovascular Diseases
  • 8.4.5. Others
• 8.5. Market Analysis, Insights and Forecast - By End User
  • 8.5.1. Pharmaceutical & Biotechnological Companies
  • 8.5.2. Academic & Research Institutes
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Brazil
    • 8.6.1.1. By Drug Type
  • 8.6.2. Mexico
    • 8.6.2.1. By Drug Type
  • 8.6.3. Rest of Latin America
    • 8.6.3.1. By Drug Type

9. Middle East & Africa Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Service Type
  • 9.1.1. Chemistry Services
    • 9.1.1.1. Synthetic Chemistry Services
    • 9.1.1.2. Analytical Chemistry Services
    • 9.1.1.3. Others
  • 9.1.2. Biology Services
    • 9.1.2.1. In-vitro Profiling Services
    • 9.1.2.2. Toxicology Services
    • 9.1.2.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 9.2.1. Target Identification & Validation
  • 9.2.2. Hit Identification
  • 9.2.3. Hit-to-Lead
  • 9.2.4. Lead Optimization
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Drug Type
  • 9.3.1. Small Molecules
  • 9.3.2. Biologics
• 9.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 9.4.1. Oncology
  • 9.4.2. Neurological Diseases
  • 9.4.3. Infectious Diseases
  • 9.4.4. Cardiovascular Diseases
  • 9.4.5. Others
• 9.5. Market Analysis, Insights and Forecast - By End User
  • 9.5.1. Pharmaceutical & Biotechnological Companies
  • 9.5.2. Academic & Research Institutes
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. GCC
    • 9.6.1.1. By Drug Type
  • 9.6.2. South Africa
    • 9.6.2.1. By Drug Type
  • 9.6.3. Rest of Middle East & Africa
    • 9.6.3.1. By Drug Type

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Charles River Laboratories
  • 10.2.2. WuXi AppTec
  • 10.2.3. Labcorp
  • 10.2.4. Evotec
  • 10.2.5. Eurofins Scientific
  • 10.2.6. Reaction Biology
  • 10.2.7. Pharmaron
  • 10.2.8. Aragen Life Sciences Ltd.
  • 10.2.9. Sai Life Sciences Limited
  • 10.2.10. Crown Bioscience